Latest News and Press Releases

Fangzhou expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%

Fangzhou plans to allocate approximately 90% of the net proceeds to accelerate development of the Company's AI-driven chronic disease management platform.

Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution.

Fangzhou was recognized with the “Social Responsibility Golden Bull Award”.

Fangzhou was presented with a Generative AI Service Filing Certificate at the first Guangdong Provincial LLM Filing Conference.

Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition

Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration.

Fangzhou's “XingShi” Large Language Model (“XS LLM”) was featured by Nature News.

was recognized as an “Outstanding Growth Story in Hong Kong Stocks”

Fangzhou announced the release of its proprietary “XingShi” Large Language Model.